FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0	287				
Estimated average burden						
nours per response	э	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)														
1. Name and Address of Reporting Person * NEIS JOHN				2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 11/14/2017						Office	er (give title belo	ow)	Other (specify	below)		
(Street)				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
MADISON, WI 53716 (City) (State) (Zip)					Table I - Non-Derivative Securities Acqui							ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year	Execu any	2A. Deemed Execution Date, i	3. Transact Code (Instr. 8)		tion 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form:	7. Nature of Indirect Beneficial			
				(Mon		Co	de	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	
	Stock, par per share	value	11/14/2017			S	<u>1)</u>		5,214		S 1.4942 <u>2)</u>	626,103	3		I	See Footnote
Reminder: indirectly.	Report on a	separate line	for each class of se	curities	beneficially	owne		Pers	sons wh	n this fo	orm ar	e not req	ection of ir juired to re	espond un	less	SEC 1474 (9- 02)
			Table II		tive Securit uts, calls, w								i			
Security	Conversion	e (Month/Day/Year) any (Month/E	Date, if	4. Transaction Code Year) (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		Am Und Sec	nount of derlying Security (Instr. 5 and		f 9. Number of e Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owner Form of Deriva Securit Direct or Indi	tive Ownershi ty: (Instr. 4) rect	
					Code V	(A)	(D)	Dat Exe	te ercisable	Expirati Date	on Titl	Amount or e Number of Shares				

Reporting Owners

Donostino Ormon Nomo / Adduses	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
NEIS JOHN							
C/O CELLECTAR BIOSCIENCES, INC.	X						
3301 AGRICULTURE DRIVE	Λ						
MADISON, WI 53716							

Signatures

/s/ Christina Blakley, attorney-in-fact for John Neis	11/14/2017	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Advantage Capital Wisconsin Partners I, Limited Partnership sold 5,214 shares which represented all of its Cellectar holdings in order for the fund to make its final distributions and dissolve before the end of 2017.

The price reported in Column 4 of Line 1 with respect to the 5,214 shares sold on November 14, 2017 is a weighted average price. These shares were sold in multiple

- (2) transactions at prices ranging from \$1.46 to \$1.53. The reporting person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (2) to this Form 4.
- These securities are held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the submanager and special limited partner of (3) Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture Investors LLC are made collectively by five managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.